108 patents
Page 5 of 6
Utility
Ethers, Secondary Amines and Derivatives Thereof As Modulators of the 5-HT2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
5 Aug 20
Bradley Teegarden, Dennis Chapman, Marc Decaire, Peter I. Dosa, Konrad Feichtinger, Honnappa Jayakumar, Thuy-Anh Tran, Sonja Strah-Pleynet, Jay Xu
Filed: 10 Sep 19
Utility
Method of treating conditions related to the PGI2 receptor
22 Jun 20
Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
Alan Glicklich
Filed: 5 Dec 19
Utility
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
22 Jun 20
Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
Filed: 5 Nov 18
Utility
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders
8 Jun 20
The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).
Anthony C. Blackburn, Ryan O. Castro, Mark Allen Hadd, You-An Ma, Antonio Garrido Montalban, Jaimie Karyn Rueter, Lee Alani Selvey, Sagar Raj Shakya, Marlon Carlos
Filed: 8 Apr 19
Utility
Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
1 Jun 20
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.
Thuy-Anh Tran, Weichao Chen, Bryan A. Kramer, Abu J. M. Sadeque, Anna Shifrina, Young-Jun Shin, Pureza Vallar, Ning Zou
Filed: 1 Mar 17
Utility
Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
25 May 20
The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor.
Thuy-Anh Tran, Quyen-Quyen Do, Brett Ullman, Anthony C. Blackburn, Maiko Nagura
Filed: 5 Sep 19
Utility
Processes Useful for the Preparation of 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA and Crystalline Forms Related Thereto
6 May 20
The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.
Marlon CARLOS, Weitong DONG, Mark MACIAS, Suzanne Michiko SATO, Lee Alani SELVEY
Filed: 25 Dec 19
Utility
Compounds and Methods for Treatment of Nafld and Nash
29 Apr 20
The present invention relates to 4-[6-(6-Methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester (Compound 1), pharmaceutically acceptable salts, solvates, and hydrates thereof that modulate the activity of the GPR119 receptor.
John W. Adams, Que Liu
Filed: 18 Jun 18
Utility
Cannabinoid receptor modulators
27 Apr 20
Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
Filed: 7 Feb 17
Utility
5-HT
20 Apr 20
Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor.
Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
Filed: 11 Mar 19
Utility
Method of Treating Conditions Related to the PGI2 Receptor
8 Apr 20
Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
Alan Glicklich
Filed: 5 Dec 19
Utility
Compounds and Methods for Treatment of Visceral Pain
11 Mar 20
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof and their use in methods for the alleviation and/or treatment of visceral pain, for example abdominal pain; pelvic pain; male pelvic pain; pain from an internal organ; bladder pain; painful bladder syndrome; post-surgical abdominal pain (e.g., GI resection, hysterectomy, oophorectomy, C-section, and the like); or pain arising from or related to: pancreatitis (e.g., chronic pancreatitis), prostatitis (e.g., chronic prostatitis), inflammatory bowel disease (e.g., Crohn's disease), endometriosis, interstitial cystitis, prostatitis (e.g., chronic prostatitis), epididymitis (e.g., chronic epididymitis), or post-surgical abdominal lesions.
Cheryl Geraldine Lassen, Marcelo Fabian Piccirillo
Filed: 7 May 18
Utility
5-HT2C Receptor Agonists and Compositions and Methods of Use
11 Mar 20
Juerg Lehmann, Konrad Feichtinger, Albert S. Ren, Graeme Semple
Filed: 11 Mar 19
Utility
Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
9 Mar 20
The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation.
Lee Alani Selvey, Marlon Carlos, Paul Maffuid, Yun Shan, William L. Betts, III, Deam Windate Given, III, Ryan M. Hart, Zezhi Jesse Shao
Filed: 26 Sep 18
Utility
Cannabinoid Receptor Modulators
4 Mar 20
Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
Filed: 16 Jun 19
Utility
Pyrazole Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
12 Feb 20
Yifeng XIONG, Martin C. CHERRIER, Jin Sun Karoline CHOI, Peter I. DOSA, Brian M. SMITH, Sonja STRAH-PLEYNET, Brett ULLMAN, Bradley TEEGARDEN
Filed: 17 Apr 19
Utility
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
27 Jan 20
The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.
Marlon Carlos, Weitong Dong, Mark Macias, Suzanne Michiko Sato, Lee Alani Selvey
Filed: 6 Aug 18
Utility
Method of treating conditions related to the PGI2 receptor
20 Jan 20
Provided in some embodiments are titration packages, kits, and methods of treating pulmonary arterial hypertension comprising prescribing and/or administering to a patient in need thereof 2-(((1r,4r)-4-(((4-chlorophenyl) (phenyl)carbamoyloxy)methyl)cyclohexyl)methoxy)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, via a titration scheme that comprises the up-titration of Compound 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, over a period of no more than about nine weeks until an optimized dose is administered.
Alan Glicklich
Filed: 21 Oct 15
Utility
Cannabinoid Receptor Modulators
15 Jan 20
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.
Robert M. Jones, Sangdon Han, Lars Thoresen, Jae-Kyu Jung, Sonja Strah-Pleynet, Xiuwen Zhu, Yifeng Xiong, Dawei Yue
Filed: 23 Sep 19
Utility
Compounds and Methods for Treatment of Inflammatory Bowel Disease with Extra-intestinal Manifestations
15 Jan 20
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(triflu-oromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of extra-intestinal manifestations (EIM) in an individual with inflammatory bowel disease (BBD) and for the treatment of pyoderma gangrenosum (PG).
Cheryl Geraldine Lassen
Filed: 15 Feb 18